298 related articles for article (PubMed ID: 17852429)
1. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population.
Pehlivanov B; Orbetzova M
Gynecol Endocrinol; 2007 Oct; 23(10):604-9. PubMed ID: 17852429
[TBL] [Abstract][Full Text] [Related]
2. [Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, in Bulgarian population].
Kavardzhikova S; Pechlivanov B
Akush Ginekol (Sofiia); 2010; 49(4):32-7. PubMed ID: 20734639
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women.
Chae SJ; Kim JJ; Choi YM; Hwang KR; Jee BC; Ku SY; Suh CS; Kim SH; Kim JG; Moon SY
Hum Reprod; 2008 Aug; 23(8):1924-31. PubMed ID: 18579512
[TBL] [Abstract][Full Text] [Related]
5. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
6. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
Yilmaz M; Isaoglu U; Delibas IB; Kadanali S
J Obstet Gynaecol Res; 2011 Aug; 37(8):1020-6. PubMed ID: 21481088
[TBL] [Abstract][Full Text] [Related]
7. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism.
Dewailly D; Catteau-Jonard S; Reyss AC; Leroy M; Pigny P
J Clin Endocrinol Metab; 2006 Oct; 91(10):3922-7. PubMed ID: 16849400
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups.
Chang WY; Knochenhauer ES; Bartolucci AA; Azziz R
Fertil Steril; 2005 Jun; 83(6):1717-23. PubMed ID: 15950641
[TBL] [Abstract][Full Text] [Related]
9. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
10. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
[TBL] [Abstract][Full Text] [Related]
11. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors.
Broekmans FJ; Knauff EA; Valkenburg O; Laven JS; Eijkemans MJ; Fauser BC
BJOG; 2006 Oct; 113(10):1210-7. PubMed ID: 16972863
[TBL] [Abstract][Full Text] [Related]
12. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?
Ozkaya E; Cakir E; Cinar M; Kara F; Baser E; Cakir C; Kucukozkan T
Gynecol Endocrinol; 2012 Jun; 28(6):468-71. PubMed ID: 22103710
[TBL] [Abstract][Full Text] [Related]
13. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
[TBL] [Abstract][Full Text] [Related]
14. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
[TBL] [Abstract][Full Text] [Related]
15. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome.
Hart R; Hickey M; Franks S
Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):671-83. PubMed ID: 15380140
[TBL] [Abstract][Full Text] [Related]
16. Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOS.
Cupisti S; Dittrich R; Binder H; Kajaia N; Hoffmann I; Maltaris T; Beckmann MW; Mueller A
Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):380-6. PubMed ID: 17701884
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.
Panidis D; Tziomalos K; Misichronis G; Papadakis E; Betsas G; Katsikis I; Macut D
Hum Reprod; 2012 Feb; 27(2):541-9. PubMed ID: 22144419
[TBL] [Abstract][Full Text] [Related]
18. Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome.
Thomann R; Rossinelli N; Keller U; Tirri BF; De Geyter C; Ruiz J; Kränzlin M; Puder JJ
Gynecol Endocrinol; 2008 Apr; 24(4):199-206. PubMed ID: 18382906
[TBL] [Abstract][Full Text] [Related]
19. Higher metabolic risk with National Institutes of Health versus Rotterdam diagnostic criteria for polycystic ovarian syndrome in Turkish women.
Anaforoglu I; Algun E; Incecayir O; Ersoy K
Metab Syndr Relat Disord; 2011 Oct; 9(5):375-80. PubMed ID: 21657888
[TBL] [Abstract][Full Text] [Related]
20. Endocrinological markers for assessing hyperandrogenemia in women classified as having polycystic ovary syndrome (PCOS) according to the revised 2003 diagnostic criteria.
Mueller A; Dittrich R; Binder H; Hoffmann I; Beckmann MW; Cupisti S
Eur J Med Res; 2006 Dec; 11(12):540-4. PubMed ID: 17182367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
